Short Interest in Talphera, Inc. (NASDAQ:TLPH) Decreases By 38.1%

Talphera, Inc. (NASDAQ:TLPH) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 52,400 shares, a decrease of 38.1% from the August 31st total of 84,700 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily volume of 58,700 shares, the short-interest ratio is currently 0.9 days.

Hedge Funds Weigh In On Talphera

An institutional investor recently bought a new position in Talphera stock. Turtle Creek Wealth Advisors LLC bought a new stake in Talphera, Inc. (NASDAQ:TLPH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 71,500 shares of the company’s stock, valued at approximately $64,000. Turtle Creek Wealth Advisors LLC owned approximately 0.42% of Talphera as of its most recent filing with the Securities and Exchange Commission. 37.67% of the stock is owned by institutional investors and hedge funds.

Talphera Trading Up 6.1 %

TLPH stock traded up $0.05 during midday trading on Friday, hitting $0.86. The stock had a trading volume of 54,060 shares, compared to its average volume of 88,383. The firm has a market capitalization of $14.60 million, a price-to-earnings ratio of -0.97 and a beta of 0.33. Talphera has a 52 week low of $0.43 and a 52 week high of $1.61. The stock has a 50-day simple moving average of $0.92 and a 200 day simple moving average of $0.98.

Talphera (NASDAQ:TLPH) last announced its earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. On average, equities analysts forecast that Talphera will post -0.73 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Talphera in a report on Friday, August 16th.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.